Hillman Capital Management Inc. Trims Stake in Biogen Inc. $BIIB

Hillman Capital Management Inc. lowered its holdings in shares of Biogen Inc. (NASDAQ:BIIB) by 8.6% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 38,354 shares of the biotechnology company’s stock after selling 3,618 shares during the period. Biogen makes up 3.1% of Hillman Capital Management Inc.’s investment portfolio, making the stock its 14th largest holding. Hillman Capital Management Inc.’s holdings in Biogen were worth $5,373,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of BIIB. Elevation Point Wealth Partners LLC purchased a new stake in shares of Biogen in the 2nd quarter worth approximately $25,000. Rothschild Investment LLC raised its stake in Biogen by 64.7% during the second quarter. Rothschild Investment LLC now owns 224 shares of the biotechnology company’s stock valued at $28,000 after buying an additional 88 shares during the last quarter. Accredited Wealth Management LLC boosted its holdings in Biogen by 1,233.3% in the third quarter. Accredited Wealth Management LLC now owns 200 shares of the biotechnology company’s stock worth $28,000 after acquiring an additional 185 shares in the last quarter. WFA of San Diego LLC purchased a new stake in shares of Biogen in the second quarter worth $32,000. Finally, True Wealth Design LLC increased its holdings in shares of Biogen by 62.9% during the third quarter. True Wealth Design LLC now owns 233 shares of the biotechnology company’s stock valued at $33,000 after acquiring an additional 90 shares in the last quarter. Hedge funds and other institutional investors own 87.93% of the company’s stock.

Biogen Stock Down 1.8%

Shares of NASDAQ BIIB opened at $181.55 on Monday. The company has a current ratio of 2.68, a quick ratio of 2.03 and a debt-to-equity ratio of 0.34. Biogen Inc. has a 12-month low of $110.04 and a 12-month high of $202.41. The firm’s 50-day moving average price is $184.10 and its 200-day moving average price is $167.19. The stock has a market capitalization of $26.64 billion, a price-to-earnings ratio of 20.61, a P/E/G ratio of 1.44 and a beta of 0.15.

Biogen (NASDAQ:BIIB) last released its quarterly earnings results on Friday, February 6th. The biotechnology company reported $1.99 EPS for the quarter, topping the consensus estimate of $1.61 by $0.38. Biogen had a return on equity of 12.64% and a net margin of 13.07%.The company had revenue of $2.28 billion during the quarter, compared to analyst estimates of $2.21 billion. During the same quarter last year, the business posted $3.44 earnings per share. The firm’s revenue was down 7.2% on a year-over-year basis. Biogen has set its FY 2026 guidance at 15.250-16.250 EPS. On average, equities research analysts anticipate that Biogen Inc. will post 15.83 EPS for the current fiscal year.

Wall Street Analyst Weigh In

BIIB has been the topic of a number of analyst reports. Royal Bank Of Canada upped their price target on shares of Biogen from $217.00 to $233.00 and gave the stock an “outperform” rating in a research note on Monday, February 9th. Wolfe Research set a $231.00 target price on shares of Biogen in a research note on Monday, February 9th. BMO Capital Markets upped their price target on shares of Biogen from $165.00 to $196.00 and gave the company a “market perform” rating in a research report on Friday, February 6th. HSBC reissued a “reduce” rating and issued a $143.00 price objective (down from $144.00) on shares of Biogen in a research note on Wednesday, December 10th. Finally, TD Cowen upped their price objective on Biogen from $175.00 to $215.00 and gave the stock a “buy” rating in a research note on Monday, February 9th. Twelve research analysts have rated the stock with a Buy rating and fifteen have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $205.04.

Insider Activity at Biogen

In other news, insider Priya Singhal sold 2,660 shares of Biogen stock in a transaction that occurred on Monday, February 9th. The stock was sold at an average price of $199.83, for a total value of $531,547.80. Following the completion of the transaction, the insider owned 8,043 shares in the company, valued at approximately $1,607,232.69. The trade was a 24.85% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 0.18% of the company’s stock.

Biogen Company Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.